{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:44:59Z","timestamp":1792813499449,"version":"4.5.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>Pyrazinamide is a first-line drug used in the treatment of tuberculosis. High exposure to pyrazinamide and its metabolites may result in hepatotoxicity, whereas low exposure to pyrazinamide has been correlated with treatment failure of first-line antitubercular therapy.<\/jats:p>","DOI":"10.1128\/aac.00046-21","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T11:44:59Z","timestamp":1618487099000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-9819","authenticated-orcid":true,"given":"Jesper","family":"Sundell","sequence":"first","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wijk","sequence":"additional","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Bienvenu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medicine and Pharmacy, University of Rwanda, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"\u00c4bel\u00f6","sequence":"additional","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-J\u00fcrgen","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[{"name":"Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-397"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/id500028m"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1068.1000209"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.180"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.10.014"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03085-15"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03931-14"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1569"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2011.05.006"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01524-10"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02625-16"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.9.686.34067"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku136"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05894-11"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-00540-w"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00490-17"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187624"},{"key":"e_1_3_3_22_2","first-page":"230","article-title":"Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure","volume":"30","author":"Stamatakis G","year":"1988","unstructured":"Stamatakis G, Montes C, Trouvin JH, Farinotti R, Fessi H, Kenouch S, M\u00e9ry JP. 1988. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Clin Nephrol 30:230\u2013234.","journal-title":"Clin Nephrol"},{"key":"e_1_3_3_23_2","first-page":"1","article-title":"Pharmacokinetic study of pyrazinamide and pyrazinoic acid in subjects with normal renal function and patients with renal failure","volume":"44","author":"Vayre P","year":"1989","unstructured":"Vayre P, Chambraud E, Fredj G, Thuillier A. 1989. Pharmacokinetic study of pyrazinamide and pyrazinoic acid in subjects with normal renal function and patients with renal failure. Therapie 44:1\u20134. (In French.)","journal-title":"Therapie"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01866-12"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01567-09"},{"key":"e_1_3_3_26_2","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee AM","year":"2002","unstructured":"Lee AM, Mennone JZ, Jones RC, Paul WS. 2002. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuber Lung Dis 6:995\u20131000.","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"e_1_3_3_28_2","volume-title":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis.","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1806"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(80)90012-4"},{"key":"e_1_3_3_32_2","volume-title":"The end TB strategy 2014.","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. The end TB strategy 2014. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f55e2e"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2015.611055"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.10.027"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558302"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.2174\/18756921113119990006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00046-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00046-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:08:55Z","timestamp":1645484935000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00046-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.00046-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00046-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2021-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00046-21"}}